<DOC>
	<DOCNO>NCT01842126</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability range single intravenous ( IV ) subcutaneous ( SC ) dose BG00010 healthy volunteer , range multiple SC dose BG00010 participant painful lumbar radiculopathy . Secondary objective study determine single IV SC dose pharmacokinetics ( PK ) profile BG00010 healthy volunteer include assessment bioavailability compare SC exposure IV exposure participant , determine multiple SC dose PK profile BG00010 participant painful lumbar radiculopathy , assess single IV SC dose immunogenicity BG00010 healthy volunteer , assess multiple SC dose immunogenicity BG00010 participant painful lumbar radiculopathy , assess potential BG00010 reduce pain follow multiple SC administration participant painful lumbar radiculopathy .</brief_summary>
	<brief_title>Phase 1 Subcutaneous Single Multiple Ascending Dose Study BG00010 ( Neublastin )</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<criteria>Key Part I Part II Healthy Volunteers Key Part III multiple ascend dose ( MAD ) Subjects must diagnosis unilateral painful lumbar radiculopathy painful lumbar radiculopathy symptom must present 3 month prior Screening Visit . Subjects must rate pain â‰¥40 mm 100 mm visual analog scale ( VAS ) short form McGill pain questionnaire ( SFMPQ ) Screening Baseline Visits . Key Inclusion Criteria All Subjects Part I , Part II , Part III : All male subject female subject childbearing potential must practice effective contraception study willing able continue contraception 3 month last dose study treatment . Key Exclusion Criteria All Subjects Part I , Part II , Part III : History positive screen test hepatitis C infection , hepatitis B infection , positive human immunodeficiency virus ( HIV ) antibody . Subjects hepatitis B surface antigen ( HBsAg ) negative hepatitis B core antibody ( HBcAb ) positive allow participate positive HBsAb immunoglobulin G History malignancy clinically relevant ( determined Investigator ) allergies ; cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic ( related painful lumbar radiculopathy ) , dermatologic , rheumatic/joint , psychiatric , renal , and/or major disease . Relevant history illicit drug alcohol abuse ( define Investigator ) within 1 year prior Screening Visit . Female subject pregnant currently breastfeed , positive pregnancy test result Screening Baseline Visits . Previous administration neurotrophic factor , include BG00010 . Participation study another investigational drug approve therapy investigational use within 3 month prior Baseline Visit , current enrollment study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Sciatica</keyword>
</DOC>